Please assess the completion status of the following clinical trial:

Trial Title: QAX576 in Patients With Pulmonary Fibrosis Secondary to Systemic Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women between the ages of 18 and 65 years with a confirmed diagnosis of pulmonary fibrosis secondary to systemic sclerosis~* Both men and women must be willing to use two forms of contraception. Additional information regarding this requirement is available at screening~Exclusion Criteria:~* Certain medical conditions may exclude patients from participation.~* Should not have participated in another clinical study within 4 weeks of study start~* Smokers are not eligible for participation~* Blood loss of donation of 400 mL or more within 2 months of study start~* Pregnant women or women who are breast feeding~* Past medical history of clinically significant ECG abnormalities~* Connective tissue disorders other than systemic sclerosis.~* Active infection or history of systemic parasitic infection~* History of immunodeficiency diseases, including a positive HIV test result~* History of drug or alcohol abuse within 12 months of study start~* Any condition that may compromise patient safety~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): QAX576
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).